Table 4.

Treatment outcome after SML, PDT, observation and conventional laser for CSC, DME, and BRVO

	Treatment	Change in CRT (µm)	Change in BCVA (ETDRS letters)
CSC	SML	−131 (range −69.7 to −204)a	6.34 (range −15 to 20)d
	PDT	−85 (range −76 to −109.8)b	3.87 (range 2 to 8.5)b
	Observation	−25 (range 26 to −89)c	0.67 (range −2.1 to 2.5)c
DME	SML	−74.9 (range −138 to 48)e	1.26 (range −6.6 to 19)e
	Conventional laser	−43.6 (range −145 to 28.7)f	−0.29 (range −7.3 to 7.5)f
BRVO	SML	−122.59 (range −272 to −40.5)g	2.98 (range −3.5 to 9.5)g

CSC central serous chorioretinopathy, DME diabetic macular edema, BRVO branch retinal vein occlusion, BCVA best corrected visual acuity, CRT central retinal thickness, ETDRS Early Treatment Diabetic Retinopathy Study Group letters, PDT photodynamic therapy, SML subthreshold micropulse laser

^a199 patients from 11 studies, 7 studies excluded from the calculations, one due to prior PDT treatment [37], six due to absence of information about the CRT

^b100 patients from 3 studies

^c49 patients from 3 studies

^d216 patients from 14 studies, two studies excluded due to prior PDT [37, 41], two due to absence of information about the concrete BCVA [28, 31]

^e613 patients from 11 studies

^e195 patients from 7 studies

^f80 patients from 3 studies, one study excluded from the calculation due to prior conventional laser treatment [56]